Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Employees who work long hours with high job demands are more likely to develop depression

Employees who work long hours with high job demands are more likely to develop depression, suggests a study in the August Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

3 Aug 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.

31 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Duke Medicine researchers have identified biochemical changes in people taking antidepressants - but only in those whose depression improves. These changes occur in a neurotransmitter pathway that is connected to the pineal gland, the part of the endocrine system that controls the sleep cycle, suggesting an added link between sleep, depression and treatment outcomes.

19 Jul 2013

Depressive disorder patients exhibit negative bias brain imaging changes and cognitive dysfunction

...

19 Jul 2013

Assurex Health announces release of new psychiatric pharmacogenomic test panel

Assurex Health today announced the release of GeneSight Psychotropic 2.0, its lead psychiatric pharmacogenomic test panel. This latest GeneSight Psychotropic version has been updated to include four additional medications that now cover a total of 36 of the most commonly prescribed psychotropic medications in the US.

15 Jul 2013

Multimodal neuroimaging approach helps study structural and functional abnormalities in brain

Major depressive disorder is associated with a dysregulation of brain regions including the prefrontal cortex and limbic system. The relationship between structural and functional abnormalities in these brain regions in depressed patients is far from clear. However, both types of changes are assumed to underlie the symptoms of this disorder.

9 Jul 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.

21 Jun 2013

NeuroSigma announces launch of new website for Monarch eTNSTM System

NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the Monarch™ eTNSTM System.

6 Jun 2013

Low-dose ketamine anesthetic has potential to alleviate severe depression

Low-dose intravenous infusions of ketamine, a general anesthetic used in minor surgeries, given over a long period are an effective treatment for depression, Mayo Clinic researchers found. The study is published in the Journal of Psychopharmacology.

5 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

Study: Sleep disturbance may contribute to depression risk by impairing emotion regulation

A new study provides neurobiological evidence for dysfunction in the neural circuitry underlying emotion regulation in people with insomnia, which may have implications for the risk relationship between insomnia and depression.

23 May 2013

Study reinforces efficacy of NeuroStar TMS Therapy System in patients with MDD

New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder during the acute phase of therapy, which were maintained through one year of treatment.

22 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Journal provides guidance for clinicians on prescribing exercise for depressed patients

Exercise has been shown to be an effective treatment for major depressive disorder, both when used alone and in combination with other treatments.

13 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch eTNS (external trigeminal nerve stimulation) System from Health Canada.

2 May 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013